For instance, Kapogiannis et al. reported that a composite of NDE biomarkers—Aβ42, p-tau, and phosphorylated insulin receptor substrate 1 (IRS-1)—could predict the development of AD in cognitively normal individuals nearly a decade in advance [63]. The gene discussed is MAPT; the disease is Alzheimer disease.